Warfarin-induced skin necrosis, case report and survey of resources
Authors:
A. Kreze Jr; J. Koskuba; A. Zadražilová; V. Vomáčka; M. Kosák; A. Zápotocká
Authors‘ workplace:
II. interní oddělení FN Bulovka, Praha
Published in:
Transfuze Hematol. dnes,15, 2009, No. 3, p. 169-171.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Warfarin-induced skin necrosis is a rare complication of oral anticoagulation therapy affecting skin and soft tissue. In the article clinical course of a patient who developed warfarin-induced skin necrosis is described and clinical manifestations, diagnosis, treatment and prevention of this condition are discussed. To our best knowledge this is the first case of warfarin-induced skin necrosis described in the Czech Republic.
Key words:
warfarin, adverse effects, skin necrosis
Sources
1. Byrne JS, Razak A, Patchett S, et al. Warfarin skin necrosis associated protein S deficiency and mutation in the methyltetahydrofollate reductase gene. Clin Exp Dermatol 2004; 29: 35–36.
2. Varga EA, Sturm AC, Misita CP, et al. Homocysteine and MTHFR mutations. Circulation 2005; 111: e289–e293.
3. Pyeritz RE. Genetic disorders. In: McPee SJ, Papadakis MA, Tierney LM, jr. Current medical diagnosis treatment. 64th ed. New York, McGraw Hill, 2007; 1737–1742.
4. Flood EP, Redish MH, Bociek SJ, et al. Tromboflebitis migrans disseminate: Report of case in which gangrene of breast occured. New York State Jr Med 1943; 43: 1121–1124.
5. Bhat MH, Bhadada S, Bhansali A. Warfarin-induced skin necrosis: in a patient with craniopharyngioma. Neurosciensces 2006; 11: 50–52.
6. Gelwix TJ, Beeson MS. Warfarin-induced skin necrosis. Am J Emerg Med 1998; 16: 541–543.
7. Chan YC, Valenti D, Mansfield AO, et al. Warfarin induced skin necrosis. Br J Surg 2000; 87: 266–272.
8. Adverse drug reaction advisory commitee (ARDAC): Warfarin-induced skin necrosis. Austral Adverse Drug React Bull 2005; 24.
9. Essex DW, Wynn SS, Jin DK. Late-onset warfarin-induced skin necrosis: case report and review of litarature. Am J Hematol 1998; 57: 233–237.
10. Scarff CE, Baker CI, Hill P, Foley P. Late onset warfarin necrosis. Case report. Aust J Dermatol 2002; 43: 202–206.
11. Khalid KK. Warfarin-induced necrosis of the breast: case report. J Postgrad Med 2004; 50: 268–269.
12. Raifei N, Tabandeh H, Hirschbein M. Warfarin-induced skin necrosis of the eylids. Arch Opthalmol 2007; 125: 421.
13. Warkentin TT, Whitlock RP, Teoh KH. Warfarin-associated multiple digital necrosis complicating heparin induced trombocytopenia and Raynaud’s phenomen after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Am J Hematol 2004; 75: 56–62.
14. Humphries JE, Gardner JH, Connelly JE. Warfarin skin necrosis: recurrence in the absence of anticoagulant therapy. Am J Hematol 1991; 37: 197–200.
15. Jabar HBA. Warfarin-induced skin necrosis: a case report. Clin Appl Tromb Hemost 2006; 12: 101–104.
16. Beitz JM. Feature: coumadin-induced skin necrosis. Wounds 2002;14: 217–220.
17. Patel GK, Grey JE, Harding KG. Uncommon causes of ulceration. Br J Med 2006; 332: 594–596.
18. Van Zandt M. Painful abdominal ecchymotic lesions. Clin J Oncol Nurs 2002; 6: 363–365.
19. Yang Y, Algazy K. Warfarin-induced skin necrosis in patient with mutation of the prothrombin gene. N Engl J Med 1999; 340: 753.
20. Kessler P. Trombofilní stavy. Interní med 2006; 9: 374–379.
21. Jorg I, Fenyvesi T, Harenberg J. Anticoagulant-related skin reaction. Exp Opin Drug Saf 2002; 1: 278–294.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 3
Most read in this issue
- Detection of the JAK2V617F mutation in myeloproliferative disorders - an overview and own experiences
- Successful treatment of early molecular relapse of variant form of secondary acute promyelocytic leukemia with arsenic trioxide
- Warfarin-induced skin necrosis, case report and survey of resources
- The role of positron emission tomography and combined positron emission tomography with computed tomography in staging and response assessment in patients with non-Hodgkin’s lymphoma. Part II: Response evaluation